TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Changes in balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in perceived difficulty during gait and ADLs
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Disabilities of the Arm, Shoulder and Hand (Quick-DASH)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Short Form 36 (SF36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Clearance of Anal HSIL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean blood pressure change after intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change in local disease status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Oxygen utilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Suicide ideation and behavior
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Discontinuing Due to Grade 2 or Higher Arthralgia-myalgia
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Measurable Plasma Concentration (Cmax) BCT197
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC) BCT197
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose-Normalized Maximum Concentration of Plerixafor (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose-Normalized Area Under the Plerixafor Concentration Time Curve From Time 0 to 24 Hours Post-dose (AUC0-24h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in number of heavy drinking days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Social Anxiety Symptom Severity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Asthma control test (ACT)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Schirmer score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diffusion Tensor Imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Kiddie-Schedule for Affective Disorder and Schizophrenia-Epidemiological Version (K-SADS-E)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chinese version of Swanson, Nolan and Pelham IV Scale (SNAP-IV)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: embryo implantation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Mortality within 1 month during ICU stay
Endpoint domain: Mortality/survival
Primary endpoint: Modification of the expression of ADARs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Editing profile of PDE8A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensory processing (EEG: P50 suppression)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensorimotor gating (EMG: PPI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of exenatide
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of MRI in depicting lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Plasma CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body Composition (Fat Tissue Amount)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma IL-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in tumour size from baseline using RECIST 1.1 and mRECIST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in patients' beliefs and emotional functioning
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 3-yr local control rate
Endpoint domain: Mortality/survival
Primary endpoint: Modified Ashworth Scale of upper extremities spasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Objective response rate in the CNS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in CMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival status at 05 years
Endpoint domain: Mortality/survival
Primary endpoint: Change in Oral Glucose Tolerance Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: postprandial glycemia changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rapid progression of cardiac allograft vasculopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Metabolomic Principal Component Profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cmax: Maximum Observed Plasma Concentration for TAK-020
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-020
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-020
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal Disposition Phase Half-life (T1/2z) in Plasma for TAK-020
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: False positive rate of SEQureDx Trisomy 21 Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Fibromyalgia symptoms and severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of developing SBO
Endpoint domain: Mortality/survival
Primary endpoint: General ward CPR incidence
Endpoint domain: Mortality/survival
Primary endpoint: retention in care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Probability of Complete Clinical Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ipsilateral breast tumor recurrence rates
Endpoint domain: Mortality/survival
Primary endpoint: Cosmetic outcome resulting from breast conserving surgery and breast radiation
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Maximum Tolerated Dose (MTD) of Siplizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in hormone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in K-MBI score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Children's Organizational Skills Scale (COSS)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Academic Performance Rating Scale (APRS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of optimal late arterial phase acquisition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nutritional deficiencies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Discharge disposition from hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Length of stay in days for participant's hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Proportion of high-risk peptic ulcer bleeding patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Magnitude of Acoustic Amplitude Tremor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Magnitude of Acoustic Frequency Tremor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: CAPS(D) hyperarousal scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Experienced Dose Limited Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of IARs graded mild
Endpoint domain: Adverse events/effects
Primary endpoint: Change in monocyte cytokine responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: average days hospitalized
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: 24-hour Urine Albumin Excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Fibroblast Growth Factor-23 (FGF-23)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Laboratory safety results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Circulating peripheral T lymphocytes and CD4+/CD8+ subset counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Flexible sigmoidoscopy completion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean prevalence of ICU patients colonised with antimicrobial resistant Gram-negative pathogens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Participants Who Shed Any Vaccine Virus
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Shed A/H1N1 Vaccine Virus
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Shed A/H3N2 Vaccine Virus
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Shed B Vaccine Virus
Endpoint domain: Adverse events/effects
Primary endpoint: Age appropriate vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total proportion of peptic ulcers after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Capsule endoscopy findings of small-intestinal mucosal injuries after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: expression level of VEFG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PEDG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Factor VIII
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Risk of intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of patients with symptomatic intracerebral hemorrhage
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of RHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from Baseline IBS-Severity Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change from Baseline IBS-QoL score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from Baseline Trait Anxiety Inventory (STAI) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline Simple spirometry parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: body fat content and ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Asthma Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep Patterns
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Urine Hydration Biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30 day all-cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Breastfeeding status at 1 month postpartum
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Categorical shift in modified Rankin scale (mRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Prevalence of participants who reported vaginal sex
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: ASES Scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Visual Analog Scale Scores
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: SST Scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pain measurement using Visual Analog Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 4-month Progression-Free Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: Increase in CSF Aβ40 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cure rate based on VIA and colposcopy assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-24h of semaglutide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in gastrointestinal symptom occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Pain score on visual analog scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in time on labor and delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Difference in cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Phone Retention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proper Operating and Functioning of the MOMBA Application
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scores on the IAT scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mutans streptococci count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: Decline in plasma HIV-1 RNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants meeting ART re-initiation criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to meeting ART re-initiation criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Auditory Arousal Threshold (AAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain level by a numerical scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain level by using Brief Pain Inventory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain level by using QDN4 questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mobility of the shoulders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timed 25-Foot Walk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic and local adverse event rates
Endpoint domain: Adverse events/effects
Primary endpoint: Time to steady dosage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment success (complete or partial response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HP Infection Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Complete Response (CR) at the end of the chemotherapy program
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac Toxicity during the chemotherapy program
Endpoint domain: Adverse events/effects
Primary endpoint: Effects of wound solution on skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Progression of interstitial fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major complications (according to VARC 3 criteria)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of treatment-emergent serious adverse events (TE-SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Endothelial Mediated Vascular Reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Child Body Mass Index (BMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postoperative movement-evoked pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correctness of triage decision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Function of the subscapularis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Capecitabine-related toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in TSPO PET tracer uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Adverse Events (AE)/Serious Adverse Events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants That Had Complete Clearance of Actinic Keratosis (AK)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction Rate (Percent) of Actinic Keratosis (AK) Lesion Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: [11C]PBR28 uptake in brain (VT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean absolute change in haemoglobin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean absolute change in weekly epoetin dosage per kg body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavior Evaluation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: necessary dose of propofol for anesthesia induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change from Baseline IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Facial movement/animation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intubation Difficulty Scale (IDS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Dose of Levodopa/Carbidopa Tolerated
Endpoint domain: Adverse events/effects
Primary endpoint: Liver insulin sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of HbA1C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Facial Expression Identification Task (FEIT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time from induction to abortion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of Subjects With Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Bioavailability of LY3314814
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient perception related to clinical trials participation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from Baseline NIH Toolbox Picture Vocabulary Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from Baseline NIH Toolbox Oral Reading Recognition
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from Baseline NIH Toolbox Flanker Inhibitory Control and Attention Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from Baseline NIH Toolbox Dimensional Change Card Sort Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from Baseline NIH Toolbox List Sorting Working Memory Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from Baseline NIH Toolbox Oral Symbol Digit Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Electromyographic activity of masticatory muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CSF neopterin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differences in metabolite concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Intrauterine Fluid Volume Lost
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Alcohol consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body Weight variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Inflammatory Cell Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of confirmed Covid-19 cases
Endpoint domain: Mortality/survival
Primary endpoint: Mediolateral stability index (MLSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Palmitate oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hazard ratio for immune-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Depressed Mood
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percent drop in mean SBP at night-time compared to mean SBP in day-time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: changes in mean pulmonary pressure (PAPm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes